The best anti-aging peptides, separated from the longevity marketing
Longevity is where peptide marketing is least constrained by evidence. These are the compounds with a real mechanism and at least some human signal, ranked accordingly. Several famous names are in the excluded list with reasons.
Quick answer
| # | Compound | Class | Evidence | Reported range | Status |
|---|---|---|---|---|---|
| 1 | Tesamorelin | GHRH analogs | Regulator approved | 1-2 mg | Prescription |
| 2 | GHK-Cu | Healing & repair | Clinical trials | 1-2 mg | Unapproved |
| 3 | SS-31 | Mitochondrial & longevity | Clinical trials | 40-60 mg | Prescription |
| 4 | MOTS-c | Mitochondrial & longevity | Preliminary human | 5-10 mg | Research only |
| 5 | Epitalon | Bioregulators | Preliminary human | 100-200 mcg | Research only |
The ranking
An approved GHRH analog that restores IGF-1 toward younger ranges and reduces visceral fat, both of which are reasonable ageing targets. It is the only compound here with a large controlled trial base.
Plasma GHK declines markedly with age and the copper complex modulates a broad set of tissue-remodelling genes. Human dermatological trials are positive. This is anti-aging in the literal, measurable sense.
A cardiolipin-stabilising mitochondrial peptide that has been through multiple phase III trials in mitochondrial disease. The age-related muscle decline work is earlier stage but it is one of the few longevity compounds with a serious clinical programme.
An endogenous mitochondrial peptide that falls with age and rises with exercise. Three small human studies. Ranks on the quality of the biology rather than on outcome data.
Material for this compound is sold for laboratory research only. It is not manufactured, tested or labelled for human administration.
The most studied of the Khavinson bioregulators, associated with melatonin rhythm restoration and telomerase activation in cell culture. Nearly all evidence comes from one research group and has not been independently replicated.
Material for this compound is sold for laboratory research only. It is not manufactured, tested or labelled for human administration.
What we left out, and why
- FOXO4-DRI
- One mouse study and no human data whatsoever. The senolytic mechanism is interesting; the evidence does not exist yet.
- Humanin
- Observational human data only. Promising biology, no intervention trials.
- Glutathione
- Important antioxidant, poor oral bioavailability, and the injectable route is a compounded unapproved product. N-acetylcysteine is usually the more practical path.
Head-to-head comparisons
References for the compounds in this guide
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med 2026.PubMed 41476424 · doi:10.1177/03635465251357593
- Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.Obes Res Clin Pract 2026.PubMed 41545261 · doi:10.1016/j.orcp.2026.01.002
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.Drugs 2011.PubMed 21668043 · doi:10.2165/11202240-000000000-00000
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.Ann Pharmacother 2012.PubMed 22298602 · doi:10.1345/aph.1Q629
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci 2026.PubMed 42123471 · doi:10.3390/ijms27093890
- CROI 2024: Neuropsychiatric Complications in People With HIV.Top Antivir Med 2024.PubMed 39746672
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.Int J Mol Sci 2018.PubMed 29986520 · doi:10.3390/ijms19071987
- GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.Biomed Res Int 2015.PubMed 26236730 · doi:10.1155/2015/648108
- Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?.Molecules 2025.PubMed 39795193 · doi:10.3390/molecules30010136
- The human tri-peptide GHK and tissue remodeling.J Biomater Sci Polym Ed 2008.PubMed 18644225 · doi:10.1163/156856208784909435
- Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD).Cells 2021.PubMed 34572131 · doi:10.3390/cells10092483
- Elamipretide: First Approval.Drugs 2026.PubMed 41335372 · doi:10.1007/s40265-025-02269-8
- Targeting mitochondrial dysfunction with elamipretide.Heart Fail Rev 2022.PubMed 35037146 · doi:10.1007/s10741-021-10199-2
- Beyond the injection: delivery systems reshaping retinal disease management.Expert Opin Pharmacother 2025.PubMed 40319468 · doi:10.1080/14656566.2025.2496424
- Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.Int J Mol Sci 2025.PubMed 39940712 · doi:10.3390/ijms26030944
- Mitochondrial Dysfunction: The Silent Catalyst of Kidney Disease Progression.Cells 2025.PubMed 40497970 · doi:10.3390/cells14110794
- Advances in primary mitochondrial myopathies.Curr Opin Neurol 2019.PubMed 31408013 · doi:10.1097/WCO.0000000000000743
- MOTS-c: A potential anti-pulmonary fibrosis factor derived by mitochondria.Mitochondrion 2023.PubMed 37307934 · doi:10.1016/j.mito.2023.06.002
- MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases.Int J Mol Sci 2022.PubMed 36233287 · doi:10.3390/ijms231911991
- MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases.J Transl Med 2026.PubMed 42243958 · doi:10.1186/s12967-026-08398-2
- MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism.Free Radic Biol Med 2016.PubMed 27216708 · doi:10.1016/j.freeradbiomed.2016.05.015
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.Front Endocrinol (Lausanne) 2023.PubMed 36761202 · doi:10.3389/fendo.2023.1120533
Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.